Krystal Biotech (KRYS) 10% Owner Krishnan Krish S Sells Shares

What Happened
Krishnan Krish S, a reported 10% owner of Krystal Biotech (KRYS), sold a total of 25,000 shares on 2026-09-04 in a series of open-market transactions. The trades were executed at reported weighted-average prices ranging roughly from $354 to $367 per share, producing aggregate proceeds of approximately $8.98 million (about $9.0M). These sales were reported as ordinary dispositions (S).

Key Details

• Transaction date: 2026-09-04 (all trades executed that day).
• Total shares sold: 25,000; aggregate proceeds: $8,983,082 ($9.0M).
• Reported prices per lot (weighted averages) ranged from $354.54 up to $366.56; underlying trade ranges span roughly $353.98–$366.91 per footnotes.
• The sales were made pursuant to a Rule 10b5‑1 trading plan adopted on 2025-09-04; the filing states the plan reached the maximum number of shares to be sold and has terminated (Footnote F2).
• Multiple footnotes note the trades were executed in multiple sub-trades and the reported prices are weighted averages; the filer offers to provide breakdowns on request (F3–F15, F10–F15).
• The filer may be deemed to beneficially own shares held by his spouse and certain trusts; those shares/transactions are reported separately and are disclaimed here except to the extent of any pecuniary interest (F1, F16–F18).
• Shares owned after the transactions are not specified in the information provided in this summary.
• Filing timeliness: reported and filed on 2026-09-04 (no late filing indicated).

Context
This was a sale (S) executed under a pre-established 10b5‑1 plan — a routine, scheduled disposition mechanism used by insiders to sell shares. For retail investors, purchases usually carry clearer signals than scheduled sales; this filing documents a planned liquidation that has reached its planned limit.